Catalent, Inc. (NYSE:CTLT) Director Michelle R. Ryan Sells 2,800 Shares

Catalent, Inc. (NYSE:CTLT) Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the transaction, the director now directly owns 10,835 shares in the company, valued at approximately $646,849.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Catalent Trading Up 0.2 %

NYSE CTLT traded up $0.14 during mid-day trading on Thursday, hitting $59.29. The company’s stock had a trading volume of 518,676 shares, compared to its average volume of 2,034,556. The firm has a market capitalization of $10.76 billion, a P/E ratio of -26.17, a price-to-earnings-growth ratio of 2.36 and a beta of 1.16. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. Catalent, Inc. has a 52-week low of $36.00 and a 52-week high of $61.20. The stock’s fifty day simple moving average is $59.89 and its two-hundred day simple moving average is $58.16.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same period last year, the company posted ($0.10) earnings per share. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. Research analysts expect that Catalent, Inc. will post 0.84 EPS for the current year.

Institutional Investors Weigh In On Catalent

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in Catalent by 1.1% in the first quarter. Vanguard Group Inc. now owns 20,405,181 shares of the company’s stock valued at $1,151,872,000 after acquiring an additional 218,682 shares in the last quarter. Millennium Management LLC grew its holdings in Catalent by 129.2% during the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock valued at $229,416,000 after purchasing an additional 2,299,784 shares in the last quarter. Alpine Associates Management Inc. increased its stake in Catalent by 3.4% during the 3rd quarter. Alpine Associates Management Inc. now owns 2,131,126 shares of the company’s stock worth $129,082,000 after buying an additional 69,875 shares during the period. Bank of New York Mellon Corp lifted its holdings in Catalent by 14.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,930,621 shares of the company’s stock worth $108,559,000 after buying an additional 250,999 shares in the last quarter. Finally, Bank of Montreal Can lifted its stake in shares of Catalent by 181.5% in the third quarter. Bank of Montreal Can now owns 1,813,167 shares of the company’s stock worth $109,388,000 after acquiring an additional 1,169,044 shares in the last quarter.

Wall Street Analyst Weigh In

Several research analysts have weighed in on CTLT shares. Robert W. Baird restated a “neutral” rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. StockNews.com upgraded Catalent from a “sell” rating to a “hold” rating in a report on Thursday. Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Finally, William Blair reissued a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Nine research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $59.83.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.